HOUSE BILL 1192

By: Delegates Patterson, Crutchfield, Henson, Howell, R. Jones, and McComas
Introduced and read first time: February 11, 2022
Assigned to: Health and Government Operations

A BILL ENTITLED

AN ACT concerning

Maryland Health Care Commission – Studies of Issues Affecting Individuals With Sickle Cell Disease

FOR the purpose of requiring the Maryland Health Care Commission, in consultation with the Maryland Department of Health and certain experts and stakeholders, to conduct studies on individuals who provide medical services in emergency departments and their knowledge of sickle cell disease, the coordination of health care for individuals with sickle cell disease who are transitioning from pediatric to adult health care in the State, and Maryland Medical Assistance Program enrollees seeking medical care for sickle cell disease outside the State; requiring the Commission to provide a copy of the report to a person on request; and generally relating to studies regarding individuals with sickle cell disease.

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That:

(a) (1) The Maryland Health Care Commission, in consultation with the Maryland Department of Health, experts in sickle cell disease, individuals who provide medical care in emergency departments, and other stakeholders, shall conduct a study on individuals who provide medical services in emergency departments in the State and their knowledge of sickle cell disease.

(2) The study conducted under paragraph (1) of this subsection shall examine:

(i) the extent and type of knowledge that individuals who provide medical services in emergency departments in the State have about sickle cell disease;

(ii) the type of educational training individuals who provide medical services in emergency departments receive regarding sickle cell disease, its treatment, and how it may be affected by medical care; and

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
(iii) opportunities to educate individuals who provide medical services in emergency departments on sickle cell disease, including by requiring an individual to meet education requirements regarding sickle cell disease before being issued any certification required for providing medical care in an emergency department setting or as a component of continuing education.

(b) (1) The Maryland Health Care Commission, in consultation with the Maryland Department of Health, experts in sickle cell disease, and other stakeholders, shall conduct a study on the coordination of health care for individuals with sickle cell disease who are transitioning from pediatric to adult health care in the State.

(2) The study conducted under paragraph (1) of this subsection shall examine:

(i) resources available to individuals with sickle cell disease who are transitioning from pediatric to adult health care in the State;

(ii) the type and frequency of actions taken by health care providers in the State to coordinate health care for individuals with sickle cell disease who are transitioning from pediatric to adult health care in the State; and

(iii) opportunities to enhance health care coordination for individuals with sickle cell disease who are transitioning from pediatric to adult health care in the State.

(c) (1) The Maryland Health Care Commission, in consultation with the Maryland Department of Health, experts in sickle cell disease, Maryland Medical Assistance Program enrollees with sickle cell disease, and other stakeholders, shall conduct a study on Maryland Medical Assistance Program enrollees receiving out-of-state medical care for sickle cell disease.

(2) The study conducted under paragraph (1) of this subsection shall examine, to the extent practicable:

(i) the number of Maryland Medical Assistance Program enrollees receiving medical care for sickle cell disease outside the State, including as compared to the total number of Program enrollees with sickle cell disease;

(ii) the reasons that Maryland Medical Assistance Program enrollees seek medical care for sickle cell disease outside the State;

(iii) barriers to receiving medical care for sickle cell disease outside the State for Maryland Medical Assistance Program enrollees; and

(iv) financial consequences of Maryland Medical Assistance Program enrollees receiving care for sickle cell disease outside the State, both for the enrollees and
the Program.

(d) (1) On or before July 1, 2023, the Maryland Health Care Commission shall report its findings and recommendations resulting from the studies required under this section, in accordance with § 2–1257 of the State Government Article, to the Senate Education, Health, and Environmental Affairs Committee and the House Health and Government Operations Committee.

(2) The Maryland Health Care Commission shall provide a copy of the report under paragraph (1) of this subsection to any person on request.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1, 2022.